Exercise News and Research

Latest Exercise News and Research

Older Americans suffer from full-blown depression: Report

Maureen Duffy's memories of her grandmother are cloudy. Not because of time, but by a condition that cast a shadow over the woman Duffy had visited as a child.

10 Aug 2010

Raptor Pharmaceutical to raise $15 million through PIPE financing

Raptor Pharmaceutical Corp., announced it has entered into a securities purchase agreement in connection with a private placement, or PIPE financing. Upon the closing of the PIPE financing, Raptor will receive gross proceeds of approximately $15 million resulting from the sale of 4,897,614 units at a purchase price of $3.075 per unit.

10 Aug 2010

Ratios between males and females affect human longevity: Study

"Love stinks!" the J. Geils band told the world in 1980, and while you can certainly argue whether or not this tender and ineffable spirit of affection has a downside, working hard to find it does. It may even shorten your life.

10 Aug 2010

Virginia Attorney General, Governor talk health reform mandate; Missouri vote still reverberating

NPR's Weekend Edition Sunday interviewed Virginia Attorney General Ken Cuccinelli about the state's challenge to the federal government's health law requiring people to purchase health insurance. Cuccinelli said a judge that refused to throw out his case "did not say it's unconstitutional. But he did say that this legislation goes farther than anything that has been held constitutional under the Commerce Clause and it goes farther than anything that has been held constitutional under the taxing power before.

10 Aug 2010

BioVentrix announces First-in-Man milestone for PliCath heart failure system

BioVentrix, developer of the PliCath HF™ System for use in Epicardial Catheter-based Ventricular Reconstruction (ECVR), today announced achievement of its First-in-Man milestone, performed on a 52-year-old male heart failure patient in Krakow, Poland. The PliCath HF System is designed to treat heart failure (HF) by reducing the enlarged Left Ventricle (LV) through an anchoring system that is delivered across the cardiac chambers with the use of a catheter.

9 Aug 2010

The Biggest Loser, Active.com announce launch of The Biggest Loser Event Challenge

NBC's "The Biggest Loser" and The Active Network, Inc.'s flagship website Active.com today announced the launch of The Biggest Loser Event Challenge, powered by Active.com, a series of nationwide 5K and one mile events designed to inspire Americans of all fitness levels to get moving with others.

7 Aug 2010

Orexigen second-quarter net loss decreases to $11.9 million

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the second quarter of 2010. For the quarter ended June 30, 2010, Orexigen reported a net loss of $11.9 million, or $0.25 per share attributable to common stockholders, as compared to a net loss of $17.8 million, or $0.51 per share attributable to common stockholders, for the second quarter of 2009.

7 Aug 2010

Bacterin International closes private placement

Bacterin International Holdings, Inc., a developer of anti-infective coatings for medical applications and revolutionary bone graft material, today announced that it has closed its private placement offering raising total gross proceeds of $9.2 million from the sale to accredited investors, including certain of its directors and officers, of shares of its common stock at a purchase price of $1.60 per share, with detachable warrants to purchase one-quarter of one share its common stock (at an exercise price of $2.50 per share) for each share purchased.

7 Aug 2010

ATS Medical shareholders approve acquisition by Medtronic

ATS Medical, Inc. today announced that its shareholders approved Medtronic, Inc.'s acquisition of ATS Medical for $4.00 per share in cash for each share of ATS Medical stock, which per share amount is subject to decrease in the limited circumstances described in the Agreement and Plan of Merger, dated April 28, 2010, between ATS Medical, Inc., Medtronic, Inc. and Pilgrim Merger Corporation.

7 Aug 2010

APRE training provides better results than standard techniques: Study

A strength training technique called autoregulatory progressive resistance exercise —in which athletes increase strength by progressing at their own pace—provides better results than standard techniques in which resistance is steadily increased, reports a study in The Journal of Strength and Conditioning, official research journal of the National Strength and Conditioning Association.

7 Aug 2010

Ongoing diabetes education continues to deliver better health results: Study

Preliminary data from a study of private insurance and Medicare claims commissioned by the American Association of Diabetes Educators reveal that ongoing diabetes education continues to deliver results in terms of better health and reduced private insurance and Medicare claims.

7 Aug 2010

Nabi Biopharmaceuticals reports revenue of $4.8M for second-quarter 2010

Nabi Biopharmaceuticals today announced its second quarter financial results for the three month period ended June 26, 2010. The Company reported a net loss from continuing operations of $3.4 million, or $0.08 per share, compared to a net loss of $5.8 million, or $0.11 per share, for the period ended June 27, 2009.

6 Aug 2010

Need for trained medical professionals to treat medical emergencies in high school athletes

As summer football practice gets into full swing, it's essential to be aware of the risk of exertional heat stroke (EHS) in high school athletes, according to a Safety Alert in The Journal of Strength and Conditioning Research, official research journal of the National Strength and Conditioning Association. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

6 Aug 2010

Incyte second-quarter total revenues increase to $49.8 million

Incyte Corporation today reported second quarter 2010 financial results and described progress for several of its clinical programs.

5 Aug 2010

FDA issues comprehensive evaluations that address key objectives of agency's public health mission

The U.S. Food and Drug Administration today issued two comprehensive evaluations containing recommendations that address three key objectives of the agency's public health mission as it relates to medical devices – foster device innovation, create a more predictable regulatory environment, and enhance device safety.

5 Aug 2010

Vanda second-quarter 2010 revenues decrease by $4.1M

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the second quarter and six months ended June 30, 2010.

5 Aug 2010

Diabetes Self-Management Training helps to prevent complications in pre diabetes patients

Citing research that demonstrates the cost savings and health benefits of providing Diabetes Self-Management Training (DSMT) to patients with pre-diabetes, the American Association of Diabetes Educators today called on private insurers and Medicare to include education as a covered benefit for this population.

5 Aug 2010

Teleflex announces pricing of $350 million 3.875% convertible senior subordinated notes due 2017

Teleflex Incorporated today announced that it priced its previously announced public offering of $350 million in aggregate principal amount of 3.875% convertible senior subordinated notes due 2017. In addition, Teleflex granted the underwriters an option to purchase up to an additional $50 million in aggregate principal amount of convertible notes within 13 days from the date of closing of the offering.

5 Aug 2010

Alnylam second-quarter revenues increase to $26.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2010, and company highlights.

5 Aug 2010

FDA issues Lux Biosciences Complete Response letter for Luveniq NDA

Lux Biosciences, Inc. today announced that the U.S. Food and Drug Administration's Center of Drug Evaluation and Research has issued a Complete Response letter regarding the New Drug Application (NDA) for Luveniq™ (oral voclosporin) for the treatment of non-infectious uveitis.

5 Aug 2010

Exercise News and Research

Latest Exercise News and Research

Older Americans suffer from full-blown depression: Report

Raptor Pharmaceutical to raise $15 million through PIPE financing

Ratios between males and females affect human longevity: Study

Virginia Attorney General, Governor talk health reform mandate; Missouri vote still reverberating

BioVentrix announces First-in-Man milestone for PliCath heart failure system

The Biggest Loser, Active.com announce launch of The Biggest Loser Event Challenge

Orexigen second-quarter net loss decreases to $11.9 million

Bacterin International closes private placement

ATS Medical shareholders approve acquisition by Medtronic

APRE training provides better results than standard techniques: Study

Ongoing diabetes education continues to deliver better health results: Study

Nabi Biopharmaceuticals reports revenue of $4.8M for second-quarter 2010

Need for trained medical professionals to treat medical emergencies in high school athletes

Incyte second-quarter total revenues increase to $49.8 million

FDA issues comprehensive evaluations that address key objectives of agency's public health mission

Vanda second-quarter 2010 revenues decrease by $4.1M

Diabetes Self-Management Training helps to prevent complications in pre diabetes patients

Teleflex announces pricing of $350 million 3.875% convertible senior subordinated notes due 2017

Alnylam second-quarter revenues increase to $26.6 million

FDA issues Lux Biosciences Complete Response letter for Luveniq NDA

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Exercise News and Research

Latest Exercise News and Research

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Newsletters you may be interested in